DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Phase 2

Not yet recruiting

Conditions: Lung Adenocarcinoma

Interventions: Drug: Furmonertinib

First Posted Date: 2021-07-16

Last Posted Date: 2021-07-16

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT04965831

A One-arm, Prospective Study Comparing the Effects of Different Body Composition on the Survival of Patients Undergoing Radical Concurrent Chemoradiotherapy for Esophageal Cancer

Recruiting

Conditions: Brief Description of Focus of Study

First Posted Date: 2021-06-23

Last Posted Date: 2023-04-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 120

Registration Number: NCT04936750

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital/, Tianjin, China

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Gastric Adenocarcinoma

Interventions: Drug: PD-1 antibody combined with FOLFIRINOX regimen
Drug: PD-1 antibody combined with SOX program

First Posted Date: 2021-06-01

Last Posted Date: 2021-06-01

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 124

Registration Number: NCT04908566

Locations: 🇨🇳
RuiLiu, Tianjin, Tianjin, China

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Camrelizumab
Drug: Nab-Paclitaxel
Drug: Carboplatin

First Posted Date: 2021-05-28

Last Posted Date: 2021-05-28

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 420

Registration Number: NCT04907344

Locations: 🇨🇳
Breast Cancer Department I, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
🇨🇳
Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Phase 2

Completed

Conditions: HER2-positive Advanced Breast Cancer

Interventions: Drug: Pyrotinib Maleate
Drug: Vinorelbine

First Posted Date: 2021-05-26

Last Posted Date: 2022-04-07

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT04903652

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, China

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: HER2+ Early or Locally Advanced Breast Cancer

Interventions: Drug: pyrotinib + trastuzumab + nab-paclitaxel
Drug: pertuzumab + trastuzumab + nab-paclitaxel

First Posted Date: 2021-05-25

Last Posted Date: 2021-05-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 490

Registration Number: NCT04900311

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Biological: Camrelizumab
Radiation: radiotherapy
Drug: Albumin Paclitaxel
Drug: Cisplatin

First Posted Date: 2021-05-13

Last Posted Date: 2021-05-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT04884906

Locations: 🇨🇳
TianjinCIH, Tianjin, Tianjin, China

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Phase 1

Conditions: Small Cell Lung Cancer Limited Stage

Interventions: Drug: Concurrent chemoradiotherapy plus anlotinib

First Posted Date: 2021-05-11

Last Posted Date: 2021-05-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 9

Registration Number: NCT04882033

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma
Progression to PD-1 Antibody

Interventions: Drug: SHR-6390
Drug: SHR-6390 + Camrelizumab (SHR-1210)
Drug: Camrelizumab (SHR-1210) + SHR-1020

First Posted Date: 2021-04-29

Last Posted Date: 2021-04-29

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 87

Registration Number: NCT04866381

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

Phase 2

Conditions: ESCC
Adjuvant Treatment
Lymph Node Positive
Pembrolizumab

Interventions: Drug: Pembrolizumab Injection [Keytruda]

First Posted Date: 2021-04-28

Last Posted Date: 2021-04-28

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 82

Registration Number: NCT04863079

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy